Moxonidine-13C, d3 (hydrochloride)

Moxonidine-13C, d3 hydrochloride is 13C and deuterated labeled Moxonidine hydrochloride (HY-B0374A) . Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis[1][2][3][4][5][6][7].

Product Specifications

Product Name Alternative

BDF5895-13C, d3 hydrochloride

UNSPSC

12352005

Target

Adrenergic Receptor; Imidazoline Receptor; Isotope-Labeled Compounds; LDLR

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Solubility

10 mM in DMSO

Smiles

CC1=NC(Cl)=C(C(O[13C]([2H])([2H])[2H])=N1)NC2=NCCN2.Cl

Molecular Formula

C8 13CH10D3Cl2N5O

Molecular Weight

282.15

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Aceros H, et al. Moxonidine modulates cytokine signalling and effects on cardiac cell viability. Eur J Pharmacol. 2014 Oct 5;740:168-82. |[3]Wang Y, et al. Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice. Int J Mol Sci. 2023 Feb 14;24 (4) :3857.|[4]Kim YH, et al. Modulation of N-type Ca²⁺ currents by moxonidine via imidazoline I₁ receptor activation in rat superior cervical ganglion neurons. Biochem Biophys Res Commun. 2011 Jun 17;409 (4) :645-50. |[5]Zhu QM, et al. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126 (6) :1522-30.|[6]Van Kerckhoven R, et al. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur J Pharmacol. 2000 May 26;397 (1) :113-20. |[7]Nurminen ML, et al. Effect of moxonidine on blood pressure and sympathetic tone in conscious spontaneously hypertensive rats. Eur J Pharmacol. 1998 Nov 27;362 (1) :61-7. |[8]Tsutsui H, et al. Moxonidine prevents ischemia/reperfusion-induced renal injury in rats. Eur J Pharmacol. 2009 Jan 28;603 (1-3) :73-8.